利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.035 秒)

    ERG MONOCLONAL ANTIBODIES
    5.
    发明申请
    ERG MONOCLONAL ANTIBODIES 审中-公开
    ERG单克隆抗体

    公开(公告)号：US20140370023A1

    公开(公告)日：2014-12-18

    申请号：US14287599

    申请日：2014-05-27

    申请人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

    发明人： Shiv Srivastava ,  Shyh-Han Tan ,  Albert Dobi

    IPC分类号： C07K16/32 ,  G01N33/574

    CPC分类号： C07K16/32 ,  C07K2317/56 ,  G01N33/5748

    摘要： Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting. The antibodies can also be used to inhibit the activity of ERG or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript and to treat malignancies associated with overexpression of ERG or an ERG fusion event, such as prostate cancer, Ewing's sarcoma, acute myeloid leukemia, acute T-lymphoblastic leukemia, endothelial cancer, and colon cancer.

    摘要翻译： 公开了与ERG结合的单克隆抗体或其抗原结合片段，更具体地，涉及由ERG3的第42-66位氨基酸形成的表位。 单克隆抗体可以是非人抗体（例如兔或小鼠）或具有衍生自那些非人抗体的CDR区的人源化单克隆抗体。 在其它实施方案中，单克隆抗体是嵌合的，具有非人ERG抗体的轻链和重链可变区。 还提供了使用抗体检测ERG的方法，或包含全部或部分ERG多肽的融合蛋白，例如由TMPRSS2 / ERG，SLC45A3 / ERG或NDRG1 / ERG融合转录物编码的ERG多肽，包括方法 在临床环境中检测ERG或ERG融合事件。 抗体还可用于抑制ERG或融合蛋白的活性，其包含全部或部分ERG多肽，例如由TMPRSS2 / ERG，SLC45A3 / ERG或NDRG1 / ERG融合转录物编码的ERG多肽，并治疗恶性肿瘤 与ERG的过量表达或ERG融合事件相关，例如前列腺癌，尤文氏肉瘤，急性骨髓性白血病，急性T淋巴细胞白血病，内皮癌和结肠癌。

    ERG MONOCLONAL ANTIBODIES
    7.
    发明申请
    ERG MONOCLONAL ANTIBODIES 审中-公开

    公开(公告)号：US20190185576A1

    公开(公告)日：2019-06-20

    申请号：US16277687

    申请日：2019-02-15

    申请人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

    发明人： Shiv Srivastava ,  Shyh-Han Tan ,  Albert Dobi

    IPC分类号： C07K16/32 ,  G01N33/574

    CPC分类号： C07K16/32 ,  C07K2317/56 ,  G01N33/5748

    摘要： Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting. The antibodies can also be used to inhibit the activity of ERG or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript and to treat malignancies associated with overexpression of ERG or an ERG fusion event, such as prostate cancer, Ewing's sarcoma, acute myeloid leukemia, acute T-lymphoblastic leukemia, endothelial cancer, and colon cancer.